As large-molecule drugs and weight-loss therapeutics dominate headlines, the pharmaceutical industry faces legislative pressures, funding cuts, and cascading supply chain disruptions.
It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the triple whammy of a Republican majority in the Senate, House of R
The pharma industry's challenge to Medicare drug price negotiation powers continues to rumble on, with three drugmakers asking a US appeals court to revive their lawsuits.
The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstru
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year